Human Immunology Biosciences Launches to Lead Clinical Immunology into Its Next Chapter with $120 Million Financing
Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced its launch with $120 million in financing. The company was incubated by ARCH Venture Partners and Monograph Capital, joined by Jeito Capital and unnamed institutional investors and family offices
HI-Bio is developing precision therapies for patients with immune-mediated diseases
Company launches with multiple clinical-stage programs and a robust translational toolkit with potential to address multiple diseases with high unmet medical needs
Company funded by ARCH Venture Partners, Monograph Capital, Jeito Capital and others
SOUTH SAN FRANCISCO, Nov. 1, 2022 /PRNewswire/ -- Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced its launch with $120 million in financing. The company was incubated by ARCH Venture Partners and Monograph Capital, joined by Jeito Capital and unnamed institutional investors and family offices.
